| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 10027943 | International Journal of Antimicrobial Agents | 2005 | 6 Pages | 
Abstract
												N-Methanocarbathymidine [(N)-MCT], a thymidine analogue, exhibits potent activity in cell culture against herpes simplex virus1 (HSV-1). (N)-MCT showed higher antiviral activity than ganciclovir (GCV). Continuous treatment of Vero cells with (N)-MCT immediately or 10 h post-infection (p.i.) fully prevented the development of viral infection. However, when infected cells were treated with (N)-MCT at 12 h p.i., there was only a partial inhibition (ca. 50%). Additionally, continuous treatment of infected cells with (N)-MCT for about 48 h was sufficient to achieve full prevention of viral infection without further treatment. These findings suggest the complete loss of herpes simplex thymidine kinase (HSV-tk) activity occurs after 48 h of treatment with (N)-MCT. This study helps to understand the mechanism and dynamics of antiHSV activity of (N)-MCT, which is necessary for its future development as an antiviral drug.
											Keywords
												
											Related Topics
												
													Life Sciences
													Immunology and Microbiology
													Applied Microbiology and Biotechnology
												
											Authors
												Mahmoud Huleihel, Marina Talishanisky, Harry Jr., Victor E. Marquez, James A. Kelley, David G. Johns, Riad Agbaria, 
											